Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, November 04, 2025

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment.

David Veitch, Basilea’s Chief Executive Officer, stated: “This further milestone payment for Europe reflects the significant medical need and strong growth momentum of Cresemba in the region. We are pleased to see that Cresemba continues to address this need in patients suffering from life-threatening invasive mold infections.”

Cresemba is approved and marketed in more than 70 countries, including the United States, most EU member states and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba amounted to USD 652 million in the 12 months between July 2024 and June 2025, a 27 percent growth year-on-year. [1]

Full PR available here

[1] IQVIA Analytics Link, June 2025. In-market sales reported as moving annual total (MAT) in US dollars.